Eurazeo Mulls Quick Return to Market as It Preps Fund Close

Eurazeo Mulls Quick Return to Market as It Preps Fund Close

Eurazeo is nearing a close of its third growth fund with about $1.42bn of capital, but the Paris-based asset manager is already plotting the fund’s successor, according to a person familiar with the situation. The firm aims to return to the market with its fourth...
Parexel to be acquired in $8.5bn private-equity deal

Parexel to be acquired in $8.5bn private-equity deal

Parexel has executed a definitive merger agreement, and will be acquired for $8.5 billion, the company announced today. Parexel, recently named “Best Contract Research Organization” by an independent panel for Informa Pharma Intelligence, will be acquired by EQT IX...